Table 2.
Average tumor volumes (day 20 after tumor implantation) in immunocompetent mice bearing subcutaneous 5TGM1 myeloma tumors after administration of recombinant VSV without or with 131I
| Treatment | Mice/group | Average tumor volume, mm3 plus or minus SD | 95% CI of mean (mm3) |
|
|---|---|---|---|---|
| Lower | Upper | |||
| PBS, intratumorally | 4 | 1796.0 ± 231.9 | 1427.0 | 2165 |
| PBS, intratumorally + 131I | 4 | 1809.0 ± 186.2 | 1512.1 | 2105.0 |
| VSV (Δ51)-NIS, ITintratumorally | 6 | 421.3 ± 100.2 | 316.2 | 526.4 |
| VSV (Δ51)-NIS, intratumorally + 131I | 6 | 129.0 ± 63.3 | 62.6 | 195.4 |
| VSV (Δ51)-NIS, intravenously | 6 | 558.0 ± 114.2 | 438.1 | 677.9 |
| VSV (Δ51)-NIS, intravenously + 131I | 6 | 204.0 ± 110.5 | 88.1 | 319.9 |
| VSV (Δ51)-GFP, intratumorally | 4 | 494.5 ± 166.2 | 230.1 | 758.9 |
| VSV (Δ51)-GFP, intratumorally + 131I | 4 | 524.5 ± 156.5 | 275.4 | 773.6 |
Virus was administered on days 12 and 13 (intratumorally or intravenously) and 131I (1 mCi) was given intraperitoneally on day 14 after tumor-cell inoculation.